Journal of Clinical Research & Bioethics

GWAS-follow-up Studies Identified a Connection between Abnormal LIF/JAK2/STAT1 Signaling and Overproduction of Galactose-Deficient IgA1 in the Tonsillar IgA1-Secreting Cells from Patients with IgA Nephropathy

Koshi Yamada¹, Jan Novak² and Yusuke Suzuki^{1* 1}Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan
²Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
^*Correspondence: Yusuke Suzuki, Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan, Tel: +81-3-5802-1064, Fax: +81-3-5802-1064, Email:

Received: 19-Dec-2023, Manuscript No. JCRB-23-24484; Editor assigned: 22-Dec-2023, Pre QC No. JCRB-23-24484 (PQ); Reviewed: 05-Jan-2024, QC No. JCRB-23-24484; Revised: 12-Jan-2024, Manuscript No. JCRB-23-24484 (R); Published: 22-Jan-2024, DOI: 10.35248/2155-9627.24.15.478

Description

IgA nephropathy (IgAN) is a common primary glomerulonephritis with its characteristic IgA1-containing glomerular immunodeposits. Patients with IgAN have a high rate of progression to kidney failure; up to 40% of patients reach that stage within 20-30 years since the diagnosis, despite receiving optimized standard care.

A suspected connection between IgAN and the mucosal immune system is highlighted by the fact that the main production sites of IgA1 reside in the mucosal tissues, and that a common clinical feature at the onset of IgAN is macroscopic hematuria with a concurrent upper respiratory-tract infection, i.e., synpharyngitic hematuria [1,2].

The "multi-hit hypothesis" has been proposed to explain the pathobiology of IgAN [3], wherein Galactose-deficient IgA1 (Gd- IgA1) glycoforms are recognized by Gd-IgA1-specific IgG autoantibodies to form immune complexes. These complexes bind other proteins, such as complement C3, and some of the resultant complexes may deposit in the glomeruli and induce kidney injury. Notably, serum levels of Gd-IgA1 and IgG autoantibodies are predictive of disease progression [4-7]. Although the precise location of the cells producing Gd-IgA1 in vivo is still under investigation, tonsillar B cells have been proposed to be significant producers of Gd-IgA1, potentially explaining why tonsillectomy improves clinical symptoms of some IgAN patients [8,9].

We previously demonstrated that Interleukin-6 (IL-6), a pro-inflammatory cytokine with multiple roles in immune responses, selectively increases the production of Gd-IgA1 in IgA1-producing cell lines from IgAN patients; this process is mediated by an abnormal activation of STAT3 [10]. Although serum Gd-IgA1 levels are genetically co-determined, this IL-6-mediated process can further elevate serum Gd-IgA1 levels in patients with IgAN [11-13].

Genome-Wide Association Studies (GWAS) of multi-ethnic cohorts uncovered multiple candidate genes involved in mucosal immunity that are associated with the development of IgAN [14-16]. Some of these genes, such as ITGAM and TNFSF13, encode proteins regulating mucosal lymphoid tissues involved in IgA production. A subset of patients with IgAN have elevated serum levels of A Proliferation-Inducing Ligand (APRIL), a cytokine from Tumor-Necrosis Factor (TNF) ligand superfamily member 13 encoded by the TNFSF13 gene. Furthermore, Toll- like Receptor 9 (TLR9) may be involved in the pathogenesis of IgAN via APRIL pathway that affect maturation of plasma cells [17]. Recent clinical trials have reported that administration of an inhibitor of APRIL, TACI-IgG Fc fusion protein (Atacicept), to IgAN patients decreased serum levels of Gd-IgA1 and improved proteinuria [18]. Similarly, a humanized IgG2 monoclonal antibody (Sibeprenlimab), a neutralizing antibody for APRIL, has been also reported to decrease serum levels of Gd-IgA1 and improve proteinuria [19].

Another IgAN-associated locus is the HORMAD2 locus that contains several genes, including LIF and OSM that encode cytokines called Leukemia Inhibitory Factor (LIF) and Oncostatin M (OSM), respectively. Furthermore, this GWAS locus is associated with IgAN as well as serum IgA levels and tonsillectomy [20-22]. A recent study postulated that this locus is likely involved in the development of IgAN in association with TLR9 pathways [23]. LIF is an IL-6-related cytokine that uses gp130 for signal transduction and has been previously implicated in mucosal immunity and was identified as a potential drug target [20,24]. Prior studies of LIF/OSM cytokines revealed that LIF stimulation of immortalized IgA1-producing cell lines derived from peripheral blood of IgAN patients increased Gd- IgA1 production [25]. Follow-up analyses of the signaling mechanisms implicated STAT1-mediated abnormal activation of Src-family kinases, including Lyn [26]. Lyn, identified in LIF-mediated signaling abnormalities in peripheral blood-derived IgA1-secreting cell lines from IgAN patients, is a non-receptor kinase with a key signaling role in inflammation. The corresponding gene, LYN, was recently identified as one of the 16 new IgAN- associated GWAS loci [20].

In summary, we identified that the signaling via the LIF/JAK2/ STAT1 pathway is involved in LIF-mediated Gd-IgA1 overproduction by immortalized IgA1-producing cell lines derived from tonsils of patients with IgAN [27]. Notably, studies of peripheral-blood mononuclear cells and kidney tissues indicated that enhanced activation of STAT1 in IgAN patients may affect the kidney function [28].

JAK/STAT is a major pathway that responds to and transduces inflammatory signals from extracellular ligands, such as cytokines and chemokines [29]. GWAS revealed a strong association of the genomic locus that contains LIF with the risk of IgAN [15,30]. Furthermore, other GWAS publications revealed that the same locus was associated with acute tonsilitis and chronic inflammation of tonsils leading to tonsillectomy as well as with IgA serum levels [21,22].

Conclusion

The abnormal LIF/JAK2/STAT1 signaling and the elevated production of Gd-IgA1 in tonsillar cells in IgAN patients may play a significant role in disease development and progression. Understanding the mechanisms involved in production of Gd-IgA1 in IgAN will be useful in development of future disease- specific therapies.

Disclosures

JN and YS are co-inventors on US patent application 14/318,082 (assigned to UAB Research Foundation). JN is a co-founder and co-owner of and consultant for Reliant Glycosciences, LLC.

Acknowledgements

KY and YS are supported in part by Grant-in-Aid for Scientific Research (C) KAKENHI 22K08362. JN is supported in part by National Institutes of Health grants DK078244, DK082753, and AI149431, a gift from the IGA Nephropathy Foundation, and research-acceleration funds from UAB.

References

1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-24014.

   [Crossref] [Google Scholar] [PubMed]

2. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014;124(6):2325-2332.

   [Crossref] [Google Scholar] [PubMed]

3. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795-1803.

   [Crossref] [Google Scholar] [PubMed]

4. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668-1677.

   [Crossref] [Google Scholar] [PubMed]

5. Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82:790-796.

   [Crossref] [Google Scholar] [PubMed]

6. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23(9):1579-1587.

   [Crossref] [Google Scholar] [PubMed]

7. Maixnerova D, Ling C, Hall S, Reily C, Brown R, Neprasova M, et al. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PloS One. 2019;14:e0212254.

   [Crossref] [Google Scholar] [PubMed]

8. Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, Kato M, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis. 2003;42:486-496.

   [Crossref] [Google Scholar] [PubMed]

9. Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, Kitagawa M, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010;136(3):447-455.

   [Crossref] [Google Scholar] [PubMed]

10. Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, et al. Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy. Kidney Int Rep. 2017;2(6):1194-1207.

    [Crossref] [Google Scholar] [PubMed]

11. Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19(5):1008-1014.

    [Crossref] [Google Scholar] [PubMed]

12. Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, et al. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017;13(2):e1006609.

    [Crossref] [Google Scholar] [PubMed]

13. Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158-2166.

    [Crossref] [Google Scholar] [PubMed]

14. Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21:1791-1797.

    [Crossref] [Google Scholar] [PubMed]

15. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321-327.

    [Crossref] [Google Scholar] [PubMed]

16. Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. 2012;44(2):178-182.

    [Crossref] [Google Scholar] [PubMed]

17. Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol. 2017;28(4):1227-1238.

    [Crossref] [Google Scholar] [PubMed]

18. Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, et al. Randomized Phase II JANUS Study of Atacicept in patients with IgA nephropathy and persistent Proteinuria. Kidney Int Rep. 2022;7(8):1831-1841.

    [Crossref] [Google Scholar] [PubMed]

19. Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, et al. A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy. Kidney Int Rep. 2023. DOI: 10.1056/NEJMoa230563.

    [Crossref] [Google Scholar] [PubMed]

20. Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023. 1091-1105.

    [Crossref] [Google Scholar] [PubMed]

21. Feenstra B, Bager P, Liu X, Hjalgrim H, Nohr EA, Hougaard DM, et al. Genome-wide association study identifies variants in HORMAD2 associated with tonsillectomy. J Med Genet. 2017;54(5):358-364.

    [Crossref] [Google Scholar] [PubMed]

22. Liu L, Khan A, Sanchez-Rodriguez E, Zanoni F, Li Y, Steers N, et al. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Commun. 2022;13(1):6859.

    [Google Scholar] [PubMed]

23. Wang YN, Gan T, Qu S, Xu LL, Hu Y, Liu LJ, et al. MTMR3 risk alleles enhance Toll Like Receptor 9-induced IgA immunity in IgA nephropathy. Kidney Int. 2023;104(3):562-576.

    [Crossref] [Google Scholar] [PubMed]

24. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457(7230):722-725.

    [Crossref] [Google Scholar] [PubMed]

25. Person T, King RG, Rizk DV, Novak J, Green TJ, Reily C. Cytokines and production of aberrantly O-glycosylated IgA1, the main autoantigen in IgA nephropathy. J Interferon Cytokine Res. 2022;42:301-315.

    [Crossref] [Google Scholar] [PubMed]

26. Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, et al. Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis (Basel). 2020;6:168-180.

    [Crossref] [Google Scholar] [PubMed]

27. Yamada K, Huang ZQ, Reily C, Green TJ, Suzuki H, Novak J, et al. LIF/JAK2/STAT1 signaling enhances production of galactose-deficient IgA1 by IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy. Kidney Int Rep. 2023. DOI: https://doi.org/10.1016/j.ekir.2023.11.003.

    [Crossref] [Google Scholar]

28. Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K, et al. JAK-STAT activity in peripheral blood cells and kidney tissue in IgA nephropathy. Clin J Am Soc Nephrol. 2020;15:973-982.

    [Crossref] [Google Scholar] [PubMed]

29. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542-550.

    [Crossref] [Google Scholar] [PubMed]

30. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187-1196.

    [Crossref] [Google Scholar] [PubMed]